Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 18 Diseases   32 Trials   32 Trials   839 News 


«12...4567891011121314...1516»
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), TroVax (MVA 5T4) / Oxford Biomedica, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
    [VIRTUAL] DEVELOPMENT OF A NEXT GENERATION 24-VALENT PNEUMOCOCCAL CONJUGATE VACCINE USING SITE-SPECIFIC CARRIER PROTEIN CONJUGATION () -  Jun 22, 2020 - Abstract #ISPPD2020ISPPD_143;    
    Administration of PPSV23 did not hinder immune responses induced by PCV13. These results demonstrate the utility of CFPS technology in the production of the eCRM carrier protein that enables site-specific conjugation, creating the foundation for a next generation broad-valency PCV.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    [VIRTUAL] PNEUMOCOCCAL SEROTYPE DISTRIBUTION: RECENT DATA IN ADULT POPULATIONS AROUND THE WORLD, 2017-2019 () -  Jun 22, 2020 - Abstract #ISPPD2020ISPPD_86;    
    Background: Pneumococcal disease remains a global health problem despite availability of vaccines (pneumococcal polysaccharide (PPV23) and pneumococcal conjugate vaccines (PCV))... After pediatric PCV adoption in various countries, several vaccine and non-vaccine serotypes remain responsible for a significant burden of disease among adults, informing the needs for future adult vaccines.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    [VIRTUAL] COMPARISON BETWEEN CANADIAN ADULTS 50+ AND 65+ YEARS HOSPITALIZED WITH PNEUMOCOCCAL COMMUNITY ACQUIRED PNEUMONIA () -  Jun 22, 2020 - Abstract #ISPPD2020ISPPD_36;    
    Higher valency PCVs provide increased coverage of serotypes currently causing adult disease, with PCV-20 potentially addressing ~65% of the burden. Adults 50-64 years hospitalized with pCAP contribute significantly to the burden of illness, suggesting that an expansion of PCV13 and PPV23 recommendations to adults 50+ years of age should be considered in order to optimize impact of pneumococcal vaccination programs in Canada.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    [VIRTUAL] PAIRING ACTIVE SURVEILLANCE AND HOSPITAL DISCHARGE SUMMARIES TO ESTIMATE THE INCIDENCE OF PNEUMOCOCCAL COMMUNITY ACQUIRED PNEUMONIA () -  Jun 22, 2020 - Abstract #ISPPD2020ISPPD_33;    
    Adults 50-64 years hospitalized with pCAP contribute significantly to the burden of illness, suggesting that an expansion of PCV13 and PPV23 recommendations to adults 50+ years of age should be considered in order to optimize impact of pneumococcal vaccination programs in Canada. Overall, pairing results from active surveillance to CIHI data allowed us to provide the most recent estimates of pCAP incidence in hospitalized Canadian adults.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
    Trial completion, IO biomarker, Pneumococcal vaccines:  Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults (clinicaltrials.gov) -  Jun 16, 2020   
    P1,  N=160, Completed, 
    Whereas vaccines are generally considered only from the public health perspective, flexible, comprehensive and tailored pneumococcal immunization programs, with appropriate policy support, can generate a greater positive impact on public health. Recruiting --> Completed
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    Journal:  Pneumococcal conjugate vaccine update. (Pubmed Central) -  Jun 9, 2020   
    ACIP no longer recommends routine use of PCV13 in immunocompetent adults ≥ 65 years. Three simple statements summarize guidance on intervals to follow when administering both PCV13 and PPSV23.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    [VIRTUAL] IMMUNOGENICITY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: EFFECT OF BIOLOGIC THERAPY ON THE VACCINAL RESPONSE (Poster View) -  May 22, 2020 - Abstract #EULAR2020EULAR_2146;    
    The negative impact of biologics on the vaccinal response was confirmed, especially if the vaccination was not performed at the optimal time in relation to the infusion of the drug or during monthly administration of BLM. If optimal vaccination terms are maintained during the treatment with or initiation of biologics (6 months after the last administration of RTM and 1 month before the next (or first) administration of RTM, 4 months after the last and 1 month before the next (or first) administration of BLM), the number of responders increases significantly.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    Journal:  Acute respiratory failure due to eosinophilic pneumonia following pneumococcal vaccination. (Pubmed Central) -  May 17, 2020   
    A 68-year-old woman under maintenance hemodialysis was admitted to our hospital with fever and dyspnea that had developed two days after the second vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23)...No disease recurrence was observed at the three-month follow-up. Thus, EP is a rare, but life-threating condition following pneumococcal vaccination.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    Vaccination recommendation in newly diagnosed chronic lymphocytic leukaemia: a retrospective audit () -  May 14, 2020 - Abstract #BSH2020BSH_359;    
    The British Society of Haematology guidelines recommend that all patients with CLL should be offered seasonal influenza vaccination and pneumococcal vaccination (Prenvar 13‐conjugate vaccine and then Pneumovax 23‐polysaccharide vaccine)...A standard paragraph advising on vaccinations for all new patients with CLL. This will be added to clinic letters before sign off.3Re‐audit once awareness raised and proforma implemented in 6 months time
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    Clinical, Journal:  Invasive Pneumococcal Infections in Children with Nephrotic Syndrome in Bangladesh. (Pubmed Central) -  Apr 29, 2020   
    Because S. pneumoniae was the primary cause of invasive infections, pneumococcal vaccines may be considered as a preventive intervention in children with nephrotic syndrome. Additionally, penicillin can be used to prevent and treat pneumococcal infections in children with nephrotic syndrome in Bangladesh.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    Clinical, Journal:  Pneumococcal vaccination for welders: Global deployment within a multi-national corporation. (Pubmed Central) -  Apr 17, 2020   
    Global deployment of pneumococcal vaccination for welders can be successfully undertaken by a multi-national corporation. Adoption of this practice by corporations could reduce the incidence and mortality of pneumonia among welders globally.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    Clinical, Journal:  Dosimetric comparison of helical tomotherapy and VMAT for anal cancer: A single institutional experience. (Pubmed Central) -  Apr 16, 2020   
    No differences were seen in V105%, V107%, or V110 % between techniques...Although absolute dose differences were small, the PTV V95%, small bowel V30, V35, and V40 and bladder V35 were statistically better in the HT plans. VMAT provided a shorter delivery time by 1.45 minutes; however, our HT plans were more likely to pass tighter plan dose verification criteria than VMAT.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), pneumococcal conjugate vaccine (V114) / Merck (MSD)
    Review, Journal:  Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection. (Pubmed Central) -  Mar 21, 2020   
    The inactivated whole-cell and several protein-based vaccines are either in Phase 1 or 2 trials. Furthermore, the recent progress of nanoparticles that play important roles as delivery systems and adjuvants to improve the performance, as well as the immunogenicity of the nanovaccines, are reviewed.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    Trends in the Clinical Characteristics of Pneumococcal Pneumonia in Japanese Elderly Adults Between 2012 and 2017 (PENNSYLVANIA CONVENTION CENTER, Room 115 A-B (100 Level)) -  Mar 15, 2020 - Abstract #ATS2020ATS_3162;    
    CONCLUSIONS Although routine vaccination of PPSV23 for elderly adults was initiated in 2014 in Japan, there was no change in the mortality of pneumococcal pneumonia patients between 2012 and 2017. In the clinical practice of elderly patients with pneumococcal pneumonia, physicians need to consider patients’ age, general condition, and the existence of comorbidity disease.